William J. Gradishar, MD, on Hormone-Sensitive Breast Cancer: Guideline Updates

Posted: Friday, March 30, 2018

William J. Gradishar, MD, of the Robert H. Lurie Comprehensive Cancer Center of Northwestern University, discusses updates to the NCCN recommendations on the efficacy, safety, and utility of HER2-targeted treatments in the adjuvant setting for early-stage and advanced breast cancers.